Can a cancer drug stop the bleeding in HHT? new trial aims to find out.
NCT ID NCT04404881
First seen Mar 29, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce chronic bleeding and iron deficiency anemia in people with hereditary hemorrhagic telangiectasia (HHT). HHT causes abnormal, fragile blood vessels that bleed easily. The trial enrolled 33 adults with HHT to receive bevacizumab and will measure changes in bleeding and anemia over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.